Skip to main content
    T

    TransMedics Group Inc (TMDX)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $92.21
    +0.83 (+0.91%)

    Market Cap: $3.17B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    TransMedics Group Inc (TMDX) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect TransMedics Group (TMDX) to earn $1.67 per share in the fiscal year ending Dec 31, 2026, on revenue of $767.14M. Of 13 analysts, 9 rate the stock Buy or Strong Buy, 4 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 8 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 13 ratings average 2.08, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 69% of the ratings.

    RatingAnalystsShare
    Strong Buy323.1%
    Buy646.2%
    Hold430.8%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    13

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus rises 49.1% and revenue estimates rise 17.5%.

    Fiscal year ending Dec 31, 2026
    $1.67
    EPS consensus, revenue $767.14M
    Fiscal year ending Dec 31, 2027
    $2.49
    EPS consensus, revenue $901.36M
    Next report
    Feb 22, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$1.67$1.51 to $1.7810$767.14M$742.00M to $772.20M12
    Dec 31, 2027$2.49$2.00 to $3.1110$901.36M$867.00M to $949.00M12

    Quarterly Estimates

    The EPS consensus is $0.46 for both quarters below, ending Dec 31, 2026 and Mar 31, 2027.

    EPS range

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$0.46$0.33 to $0.5614$205.69M$186.10M to $215.57M13
    Mar 31, 2027$0.46$0.35 to $0.534$212.29M$206.20M to $221.86M5

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 8 upward and 3 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202680
    Fiscal year ending Dec 31, 202702
    Quarter ending Mar 31, 202701

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 7.1% from $1.56.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026$1.67$1.51$1.51$1.54$1.56+7.1%
    Fiscal year ending Dec 31, 2027$2.49$2.25$2.25$2.31$2.31+7.8%
    Quarter ending Mar 31, 2027$0.46$0.46$0.46$0.48$0.48-2.5%

    Frequently Asked Questions About TMDX

    What is the TMDX stock forecast?

    Consensus analyst estimates put TransMedics Group's EPS at $1.67 for the fiscal year ending Dec 31, 2026, on revenue of $767.14M. The consensus rating from 13 analysts is Buy.

    How do analysts rate TMDX stock?

    Of 13 analysts covering TransMedics Group, 3 rate it Strong Buy, 6 Buy, 4 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from TMDX next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $1.67, with estimates from $1.51 to $1.78 from 10 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $2.49, with estimates from $2.00 to $3.11 from 10 analysts.

    What revenue do analysts expect from TransMedics Group next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $767.14M, with estimates from $742.00M to $772.20M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $901.36M, with estimates from $867.00M to $949.00M.

    How many analysts cover TMDX?

    13 analysts rate TransMedics Group stock, and 10 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.